Iovance Reports Record Q2 Revenue and Expects FY Update
Iovance Biotherapeutics posted record second-quarter revenue of ~$99 million and raised gross margins, while updating investors to expect a review of its full-year revenue guidance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day